Moderna, Merck Report Positive Results From Cancer-Vaccine Study

Core Insights - The collaboration between Moderna and Merck has resulted in a cancer vaccine that significantly reduces the risk of relapse or death in melanoma patients, as evidenced by five-year data from a Phase 2b trial [1] Group 1: Clinical Trial Results - The Phase 2b trial demonstrated that the cancer vaccine effectively lowers the risk of relapse or death for patients suffering from melanoma [1]